President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Eli Lilly (LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that ...

StudyFinds' Dr. Faith Colemans explains why shopping for weight loss drugs online may save you money but endanger your health ...

DUBLIN--(BUSINESS WIRE)--The "U.S. Compounding Pharmacy Market - Industry Outlook & Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering. The U.S. compounding pharmacies ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version in early 2025 ...

"FDA continues to monitor supply and demand for these products." Since the shortage began, specialty and compounding pharmacies have been allowed to sell off-brand versions of the weight loss drug.